You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

MVASI Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: MVASI
High Confidence Patents:0
Applicants:1
BLAs:1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for MVASI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for MVASI Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for MVASI Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for MVASI (Bevacizumab-Awwb)

Introduction to MVASI

MVASI (bevacizumab-awwb) is a biosimilar of the biologic drug Avastin, which is used to treat various types of cancer, including colorectal, non-small cell lung, glioblastoma, renal cell carcinoma, cervical, and ovarian cancers. Understanding the market dynamics and financial trajectory of MVASI is crucial for stakeholders in the pharmaceutical industry.

Market Segmentation and Growth

Application Segments

The global bevacizumab biosimilar market, including MVASI, is segmented based on applications such as colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. The non-small cell lung cancer and colorectal cancer segments are expected to grow at a higher pace due to the increasing incidence and prevalence rates of these diseases[1].

Distribution Channels

The market is also segmented by distribution channels, including hospital pharmacies, online pharmacies, and others. Hospital pharmacies are expected to dominate the market due to the increasing number of hospital visits and hospital stays[1].

Regional Market

At the regional level, North America and Europe are the major contributors to the global bevacizumab biosimilar market, driven by strong clinical pipelines, increasing research and drug development activities, and the presence of major players and developed healthcare infrastructure. Asia Pacific, particularly countries like Japan, India, and China, is also expected to grow rapidly due to early availability of biosimilars and a large population base[1].

Competitive Landscape

Market Competition

The biosimilar market, including MVASI, is highly competitive. Amgen, the manufacturer of MVASI, has reported significant sales but also faces intense competition that drives down prices. For instance, in the third quarter of 2024, MVASI sales decreased by 8% year-over-year to $195 million, with expectations of continued sales erosion due to competition[2].

Price Dynamics

Competition among biosimilars and originator products is driving down prices at an overall rate of 10% to 15% per year. This trend is expected to continue, affecting the revenues of both biosimilars and originator products. For example, Amgen reported a 71% increase in MVASI sales in 2021, but this growth was offset somewhat by price declines[4].

Financial Performance

Quarterly Sales

In the first quarter of 2024, MVASI generated $202 million in sales, which was flat year-over-year. This stability in sales is notable despite the competitive landscape[5].

Annual Financial Outlook

For the full year 2024, Amgen expects continued sales erosion for MVASI due to competition. The company's overall financial performance is influenced by various factors, including higher operating and interest expenses, partially offset by higher revenues. For instance, Amgen's non-GAAP operating income increased from $2.8 billion to $3.1 billion in the first quarter of 2024, but the non-GAAP operating margin decreased by 5.1 percentage points to 43.2%[5].

Free Cash Flow and Investments

Amgen generated $0.5 billion of free cash flow in the first quarter of 2024, which was lower than the $0.7 billion in the first quarter of 2023. This decrease was driven by an $800 million tax deposit, partially offset by the timing of working capital items. The company's cash and investments totaled $9.7 billion, and debt outstanding totaled $64.0 billion as of March 31, 2024[5].

Market Drivers and Challenges

Increasing Healthcare Expenditure

Globally, rising healthcare spending, driven by an aging population and increasing prevalence of chronic diseases, supports the growth of biologics and biosimilars like MVASI. This trend is expected to continue, providing a favorable market environment[3].

Rise in Chronic Diseases

The escalating incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders necessitates the use of biologics and biosimilars. MVASI, being a cost-effective alternative to Avastin, benefits from this trend[3].

Patent Expiry of Blockbuster Biologics

The ‘patent cliff’ of several high-revenue biologics opens significant opportunities for biosimilars to enter the market. This shift is a major driver for the biosimilars industry, including MVASI[3].

Regional Opportunities

North America and Europe

These regions are major contributors to the global bevacizumab biosimilar market due to their strong clinical pipelines, research activities, and developed healthcare infrastructure. The presence of major players in these regions further propels market growth[1].

Asia Pacific

Countries like Japan, India, and China offer tremendous market opportunities due to early availability of biosimilars and a large population base. The rapid growth expected in this region is a significant factor in the overall market dynamics of MVASI[1].

Key Takeaways

  • Market Growth: The bevacizumab biosimilar market, including MVASI, is expected to grow at an 18.40% CAGR from 2023 to 2031.
  • Segmentation: The market is segmented by application and distribution channels, with non-small cell lung cancer and colorectal cancer segments growing rapidly.
  • Competition: Intense competition drives down prices, affecting revenues despite increasing sales volumes.
  • Financial Performance: MVASI sales have been stable but face erosion due to competition, influencing Amgen's overall financial outlook.
  • Market Drivers: Increasing healthcare expenditure, rise in chronic diseases, and patent expiry of blockbuster biologics drive the market.

FAQs

What is MVASI?

MVASI (bevacizumab-awwb) is a biosimilar of the biologic drug Avastin, used to treat various types of cancer.

How is the bevacizumab biosimilar market segmented?

The market is segmented by application (e.g., colorectal cancer, non-small cell lung cancer) and distribution channels (e.g., hospital pharmacies, online pharmacies).

What are the key drivers of the bevacizumab biosimilar market?

Key drivers include increasing healthcare expenditure, the rise in chronic diseases, and the patent expiry of blockbuster biologics.

How does competition affect MVASI sales?

Competition among biosimilars and originator products drives down prices, affecting revenues despite increasing sales volumes.

What is the expected growth rate of the bevacizumab biosimilar market?

The market is expected to grow at an 18.40% CAGR from 2023 to 2031.

Sources

  1. InsightAce Analytic: Bevacizumab Biosimilar Market Share, Size, Growth and Forecast to 2031.
  2. Amgen: AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS.
  3. East Street Pharmacy: The Growth of Biologics and Biosimilars in 2024.
  4. Center for Biosimilars: Amgen Reports 56% Increase in Biosimilar Sales.
  5. PR Newswire: AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.